Physician profile

Steven D Wise

Endocrinology, Diabetes & Metabolism · Dothan, AL

NPI 1659327468

$3,148.31

in general payments reported to CMS, 2019-2025

39 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $643.80 2019-2022
Amgen INC. $388.29 2019-2022
Astrazeneca Pharmaceuticals LP $287.78 2019-2022
Bayer Healthcare Pharmaceuticals INC. $231.57 2021-2022
Lilly USA, LLC $196.72 2019-2022
Corcept Therapeutics $168.58 2019-2022
Xeris Pharmaceuticals, INC. $104.08 2021-2022
Boehringer Ingelheim Pharmaceuticals, INC. $92.66 2019-2022
Dexcom, INC. $85.35 2020-2022
Ultragenyx Pharmaceutical INC. $68.16 2021-2022
Janssen Pharmaceuticals, INC $66.86 2019-2020
Ibsa Pharma INC. $58.11 2019-2022
Abbott Laboratories $47.42 2019-2020
Tandem Diabetes Care, INC. $46.67 2022
Medtronic, INC. $45.63 2021-2022
Show all 39 companies

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Steven D Wise

$3,148.31

in general payments reported 2019-2025

Years
2019-2022
Top company
Novo Nordisk INC

https://glasscript.com/doctor/74381/steven-d-wise

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.